This Solid Energy Stock Recently Extended Its Dividend Streak to 25 Years
If you are looking for a top dividend stock to own, it’s important to consider one with a good track record for growing its payout. That signals to investors that management takes the payout seriously and is committed to rewarding its shareholders. While that doesn’t mean a dividend hike is guaranteed every year, it can be a possibility for a solid, growing business. One company that may fit that profile is energy giant TC Energy (TSX:TRP)(NYSE:TRP), which announced on Feb. 14 that its Board of Directors approved a dividend increase of 3.3% -- this marks the 25th straight year that the company has boosted its payout. The new annualized dividend of $3.40 means that investors who buy the stock today will collect a yield of 5.4%. Last year, the company spun off its liquid pipelines business as it focuses on complementary segments of its operations (natural gas, natural gas storage, and power and energy). By becoming a leaner and more efficient business, that can enable TC Energy to be in a better position to achieve more growth in the years ahead, which can ensure the dividend continues to rise. As a result, TC Energy can make for a good stock to hold for years to come. As a top player in the energy market, this is a stock that can be a fairly safe investment to hold onto for the long haul. And in the past 12 months, the stock has risen by around 30% and it still trades at a fairly modest 16 times its trailing earnings.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


